Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
969.97
+11.33 (+1.18%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
362,318
Open
967.88
Bid (Size)
958.80 (1)
Ask (Size)
980.67 (1)
Prev. Close
958.64
Today's Range
957.10 - 970.56
52wk Range
684.80 - 998.33
Shares Outstanding
91,779,465
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Regeneron Announces Investor Conference Presentations
May 06, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
May 04, 2024
Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments.
Via
InvestorPlace
Exposures
Product Safety
Performance
YTD
+7.18%
+7.18%
1 Month
+3.36%
+3.36%
3 Month
+3.59%
+3.59%
6 Month
+16.53%
+16.53%
1 Year
+28.96%
+28.96%
More News
Read More
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
May 03, 2024
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts
May 03, 2024
Via
Benzinga
Industry Comparison: Evaluating Regeneron Pharmaceuticals Against Competitors In Biotechnology Industry
May 02, 2024
Via
Benzinga
Regeneron Earnings Miss; Biotech Giant's Stock Falls
May 02, 2024
Via
Investor's Business Daily
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
April 30, 2024
Via
Benzinga
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar
May 03, 2024
Via
InvestorPlace
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
May 02, 2024
Via
Benzinga
Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?
May 02, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
April 18, 2024
Via
Benzinga
REGN Stock Earnings: Regeneron Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
May 02, 2024
Via
InvestorPlace
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
May 02, 2024
Via
Benzinga
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
May 02, 2024
Via
The Motley Fool
Regeneron Reports First Quarter 2024 Financial and Operating Results
May 02, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
April 30, 2024
Via
Benzinga
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
April 29, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
April 25, 2024
Via
Benzinga
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
April 25, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
April 24, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Small-Cap Growth Stocks With Room To Run
April 24, 2024
Via
The Motley Fool
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
April 22, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
April 18, 2024
From
Kirby McInerney LLP
Via
GlobeNewswire
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm
April 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
April 17, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.